Amgen Assures MariTide's Bone Safety Profile Amid Phase 1 Data
核心洞察
Amgen reaffirms that Phase 1 study results for MariTide (maridebart cafraglutide) do not indicate any bone safety concerns.
The company states that the administration of MariTide is not associated with changes in bone mineral density.
Amgen expresses confidence in MariTide's potential and anticipates sharing Phase 2 topline data later this year.
Amgen has released a statement addressing concerns regarding the bone safety profile of MariTide (maridebart cafraglutide), formerly known as AMG 133, currently in Phase 1 clinical trials. The company explicitly stated that the Phase 1 study results do not suggest any bone safety concern or change their conviction in the promise of MariTide.
According to Amgen, the administration of MariTide is not associated with changes in bone mineral density. This statement aims to reassure stakeholders and the medical community about the drug's safety profile as it progresses through clinical development.
Amgen remains optimistic about the potential of MariTide and plans to release topline data from the Phase 2 trial later this year. This upcoming data release will provide further insights into the efficacy and safety of MariTide, potentially solidifying its position as a promising therapeutic candidate.